Context Therapeutics Inc (CNTX)

$2.00 0.20 (11.11%)

16:00 EDT CNTX Stock Quote Delayed 30 Minutes

CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024

By InvestorPlace Earnings May 8, 2024

CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 617,683

Day's Range $1.78 - $2.10

52-Week Range $0.77 - $2.10

Dividend & Yield N/A (N/A)

CNTX Stock Predictions, Articles, and Context Therapeutics Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Apr 4, 2022

If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Dec 22, 2021

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Dec 13, 2021

Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday!

CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today

By William White, InvestorPlace Writer Dec 10, 2021

Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Dec 10, 2021

Good morning, investor! It's the last day of the trading week and we're starting it with the biggest pre-market stock movers for Friday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Dec 1, 2021

Good morning, traders! We're starting off the day right with a look at the biggest pre-market stock movers for Wednesday!

7 Companies Set to IPO That Could Be the Next Big Thing

By Josh Enomoto, InvestorPlace Contributor Sep 24, 2021

While the market for IPOs is always risky and unpredictable, it’s an enticing sector that can potentially facilitate massive gains.

Context stock soars ~70% as trial partner Stemline's breast cancer drug gets FDA approval

From Seeking Alpha Jan 31, 2023

Context Therapeutics (CNTX) said its clinical trial collaborator Stemline Therapeutics' medicine Orserdu was approved by the U.S

H.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)

From TipRanks Dec 8, 2022

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of $4.00...

CNTX stock drops on early mid-stage data for breast cancer candidate (NASDAQ:CNTX)

From Seeking Alpha Dec 8, 2022

Context Therapeutics (CNTX) shed ~27% pre-market Thursday after announcing preliminary data from an ongoing Phase 2 trial for breast cancer drug ONA-XR. Find out the reasons.

Context Therapeutics (CNTX) Receives a Buy from H.C. Wainwright

From TipRanks Dec 2, 2022

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Context Therapeutics (CNTX – Research Report), with a pric...

H.C. Wainwright Remains a Buy on Context Therapeutics (CNTX)

From TipRanks Nov 10, 2022

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of $6.00. The compa...

H.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)

From TipRanks Sep 27, 2022

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Context Therapeutics (CNTX – Research Report), with a price target of...

ADVERTISEMENT